Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo

被引：0
|
作者：
Kim, C. [1 ]
Bryant, J. [1 ]
Horne, Z. [1 ]
Geyer, C. E. [1 ]
Wickerham, D. L. [1 ]
Wolmark, N. [1 ]
Paik, S. [1 ]
机构：
[1] NSABP Operat & Biostat Ctr, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [21] AUTO ANTIBODIES AND THE AMPLIFICATION OF HER2 IN BREAST CANCER. SHOULD TREATMENT REGIMES WITH TRASTUZUMAB BE INDIVIDUALIZED?
    Lauterlein, J. L.
    Ostergaard, B.
    Brandslund, I.
    ANNALS OF ONCOLOGY, 2009, 20 : 38 - 38
  • [22] MZ1 co-operates with trastuzumab in HER2 positive breast cancer
    del Mar Noblejas-Lopez, Maria
    Nieto-Jimenez, Cristina
    Galan-Moya, Eva M.
    Tebar-Garcia, David
    Carlos Montero, Juan
    Pandiella, Atanasio
    Burgos, Miguel
    Ocana, Alberto
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [23] MZ1 co-operates with trastuzumab in HER2 positive breast cancer
    María del Mar Noblejas-López
    Cristina Nieto-Jiménez
    Eva M. Galán-Moya
    David Tebar-García
    Juan Carlos Montero
    Atanasio Pandiella
    Miguel Burgos
    Alberto Ocaña
    Journal of Experimental & Clinical Cancer Research, 40
  • [24] Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, breast cancer progression, and HER2 inhibitor sensitivity
    Hanker, Ariella B.
    Jayanthan, Harikrishna Sekar
    Ye, Dan
    Lin, Chang-Ching
    Akamatsu, Hiroaki
    Sheehan, Jonathan H.
    Koch, James P.
    Sudhan, Dhivya R.
    Brewer, Monica Red
    Servetto, Alberto
    He, Jie
    Miller, Vincent A.
    Lalani, Alshad S.
    Meiler, Jens
    Arteaga, Carlos L.
    CANCER RESEARCH, 2020, 80 (04)
  • [25] Pro-apoptotic property of phytocompounds from Naringi crenulata in HER2+breast cancer cells in vitro
    Vallinayagam, Sugumari
    Rajendran, Karthikeyan
    Sekar, Vigneshkumar
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2021, 35 (01) : 354 - 365
  • [26] HER2-Positive Breast Carcinomas with Co-amplification or Gain of Chromosome 17 Centromere Locus: Report of Three Cases and an Impact on HER2 Testing
    Shin, Hyeong Chan
    Bae, Young Kyung
    Kim, Aeri
    Park, Seok Ju
    KOREAN JOURNAL OF PATHOLOGY, 2011, 45 (06) : 665 - 669
  • [27] Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Seidman, AD
    Fornier, MN
    Esteva, FJ
    Tan, L
    Kaptain, S
    Bach, A
    Panageas, KS
    Arroyo, C
    Valero, V
    Currie, V
    Gilewski, T
    Theodoulou, M
    Moynahan, ME
    Moasser, M
    Sklarin, N
    Dickler, M
    D'Andrea, G
    Cristofanilli, M
    Rivera, E
    Hortobagyi, GN
    Norton, L
    Hudis, CA
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2587 - 2595
  • [28] A case of metastatic breast cancer with HER2 gene amplification that responded completely to single agent trastuzumab.
    Tsutani Y.
    Ohsumi S.
    Aogi K.
    Taira N.
    Kataoka M.
    Hamamoto Y.
    Nishimura R.
    Takashima S.
    Breast Cancer, 2006, 13 (4) : 374 - 377
  • [29] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [30] Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
    Silvia Antolín
    Lucía García-Caballero
    Cristina Reboredo
    Aurea Molina
    Joaquín Mosquera
    Ángel Vázquez-Boquete
    Rosalía Gallego
    Mari Paz Santiago
    Ángel Concha
    Eva Pérez
    Lourdes Calvo
    Tomás García-Caballero
    Virchows Archiv, 2021, 479 : 853 - 857
12345